Spero Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | — | $62.5M | $72.1M |
| Jun 2022 | — | $35.9M | $45.4M |
| Sep 2022 | — | $32.5M | $50.4M |
| Dec 2022 | — | $75.9M | $109.1M |
| Mar 2023 | — | $64.8M | $96.3M |
| Jun 2023 | — | $54.8M | $77.7M |
| Sep 2023 | — | $53.7M | $93.8M |
| Dec 2023 | — | $106.9M | $76.3M |
| Mar 2024 | — | $96.2M | $82.3M |
| Jun 2024 | — | $80.5M | $63.5M |
| Sep 2024 | — | $65.5M | $76.3M |
| Dec 2024 | — | $46.1M | $52.9M |
| Mar 2025 | — | $33.8M | $48.9M |
| Jun 2025 | — | $32.8M | $31.2M |
| Sep 2025 | — | $26.5M | $48.6M |
| Dec 2025 | — | $59.0M | $40.3M |
| Mar 2026 | — | $52.9M | $56.1M |
| Jun 2026 | — | $44.2M | $50.8M |